Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | SCN2B | O60939 | 4/20 | 0.36 |
| ▸ | SCN1B | Q07699 | 4/20 | 0.36 |
| ▸ | SCN1A | P35498 | 2/20 | 0.36 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530133 | 0.88 | SCN9A (0.41) | SCN9ASCN5AMAPTKDM4E | |
| SCHEMBL2532896 | 0.86 | KMO (0.42) | MAPTSETD2KDM4EKIF11HPGD | |
| SCHEMBL2532753 | 0.86 | SCN9A (0.39) | SCN9ASCN5AMAPTSCN2BSCN1B | |
| SCHEMBL14331222 | 0.85 | HTR1D (0.39) | MAPTSETD2KDM4EKIF11ABHD6 | |
| SCHEMBL2530612 | 0.85 | SCN9A (0.39) | SCN9ASCN5AMAPTSCN2BSCN1B | |
| SCHEMBL2529635 | 0.83 | SCN9A (0.39) | SCN9ASCN5AMAPTSCN2BSCN1B | |
| SCHEMBL2532541 | 0.82 | SCN9A (0.42) | SCN9ASCN5AMAPTSCN2BSCN1B | |
| SCHEMBL2532917 | 0.82 | SCN9A (0.38) | SCN9AMAPTKDM4EHPGDABHD6 | |
| SCHEMBL2537484 | 0.81 | SIRT2 (0.45) | MAPTKDM4EHPGD | |
| SCHEMBL15510176 | 0.80 | KIF11 (0.38) | MAPTSETD2KDM4EKIF11ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558449-B1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-05 | — | — | EP | claimed |
| WO-2011128251-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | claimed |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2011-10-20 | — | — | US | claimed |
| US-8586747-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130023518-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | Hoffmann-La Roche Inc (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023518-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | Hoffmann-La Roche Inc (US) | 2013-01-24 | — | — | US | disclosed |
| US-8344137-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344137-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011128251-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128251-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2011-10-20 | — | — | US | disclosed |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2011-10-20 | — | — | US | disclosed |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | QDPR, PRMT3, PRMT1 | SCN9A 1025/4885SCN5A 267/4885MAPT 3094/4885 |
| US-20130023518-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | QDPR, PRMT3, PRMT1 | SCN9A 1025/4885SCN5A 267/4885MAPT 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.